172 related articles for article (PubMed ID: 10519940)
1. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
[TBL] [Abstract][Full Text] [Related]
2. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
[TBL] [Abstract][Full Text] [Related]
3. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
[TBL] [Abstract][Full Text] [Related]
4. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
[TBL] [Abstract][Full Text] [Related]
5. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
[TBL] [Abstract][Full Text] [Related]
6. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
Tao T; Skiadopoulos MH; Davoodi F; Surman SR; Collins PL; Murphy BR
Vaccine; 2001 Jun; 19(27):3620-31. PubMed ID: 11395195
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
[TBL] [Abstract][Full Text] [Related]
8. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
[TBL] [Abstract][Full Text] [Related]
9. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
Skiadopoulos MH; Surman S; Tatem JM; Paschalis M; Wu SL; Udem SA; Durbin AP; Collins PL; Murphy BR
J Virol; 1999 Feb; 73(2):1374-81. PubMed ID: 9882342
[TBL] [Abstract][Full Text] [Related]
10. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
Skiadopoulos MH; Surman SR; Durbin AP; Collins PL; Murphy BR
Virology; 2000 Jun; 272(1):225-34. PubMed ID: 10873765
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
[TBL] [Abstract][Full Text] [Related]
12. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
[TBL] [Abstract][Full Text] [Related]
13. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
Whitehead SS; Hill MG; Firestone CY; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 1999 Dec; 73(12):9773-80. PubMed ID: 10559287
[TBL] [Abstract][Full Text] [Related]
14. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
Nelson CL; Tang RS; Stillman EA
Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2017 Dec; 35(51):7139-7146. PubMed ID: 29153777
[TBL] [Abstract][Full Text] [Related]
16. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
[TBL] [Abstract][Full Text] [Related]
17. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).
Stokes A; Tierney EL; Sarris CM; Murphy BR; Hall SL
Virus Res; 1993 Oct; 30(1):43-52. PubMed ID: 8266719
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
